Administration of high-dose aprotinin during nonprimary cardiovascular surgery: Case reports and review of the literature

Charles W. Whitten, Paul M. Allison, Lisa M. Morse, Terry W. Latson

Research output: Contribution to journalArticle

4 Scopus citations


The perioperative management of two patients undergoing complex "redo" cardiac surgical procedures are presented. The management of both patients included the prophylactic administration of aprotinin via a "compassionate use" protocol. Aprotinin, a serine protease inhibitor, has been shown to limit the exposure to blood and blood products in patients undergoing high-risk cardiac surgical procedures. In late December 1993, the Food and Drug Administration approved aprotinin for administration to cardiac surgical patients considered at high risk for post-cardiopulmonary bypass coagulopathies. Indications for the administration of aprotinin, as well as a brief review of the literature relating to the perioperative administration of aprotinin, are included.

Original languageEnglish (US)
Pages (from-to)515-520
Number of pages6
JournalJournal of Clinical Anesthesia
Issue number6
Publication statusPublished - 1994



  • Aprotinin
  • cardiopulmonary bypass
  • hemostasis
  • surgery, cardiac

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this